Pieramico O, Zanetti M V, Innerhofer M, Malfertheiner P
Department of Internal Medicine, General Hospital, Merano, Italy.
Helicobacter. 1997 Jun;2(2):92-7. doi: 10.1111/j.1523-5378.1997.tb00065.x.
It was our goal to evaluate the efficacy and safety and patient compliance with omeprazole-based dual and triple therapy for eradication of Helicobacter pylori in peptic ulcer disease.
One hundred seventy-five consecutive patients with H. pylori infection and associated active peptic ulcer were included. H. pylori infection was assessed by rapid urease test and histological analysis. Patients were randomized among three treatments: group 1 (56 patients): omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, for 2 weeks; group 2 (61 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and metronidazole, 500 mg bid, for 1 week; and group 3 (58 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and clarithromycin, 500 mg bid, for 1 week. Ulcer healing and cure of infection were evaluated at 4 to 6 weeks after cessation of therapy. Eradication rate was calculated per-protocol and by an intention-to-treat analysis.
At posttreatment endoscopy, duodenal ulcer was healed in 98.3% of patients. Eleven patients (6%) were lost to follow-up. H. pylori infection was treated successfully in 55% (95% confidence interval [CI] = 41%-69%) of patients of group 1; 86% (95% CI = 77%-95%) of group 2 (p < .001 vs. group 1); and 93% (95% CI = 85%-100%) of group 3 (p < .001 vs. group 1). On intention-to-treat analysis, eradication was 52%, 80%, and 86% in groups 1, 2, and 3, respectively. A good compliance was observed in more than 90% of patients of all groups. Side effects were reported by 7% of patients in group 1, 9% in group 2, and 11% in group 3. None of the patients stopped therapy because of side effects.
Dual-therapy omeprazole-amoxicillin for 2 weeks is associated with significantly lower eradication rate than is 1-week omeprazole-based triple therapies. Triple therapy is well-tolerated and produces side effects similar to those of dual therapy. The highest cure rate of H. pylori infection was achieved with triple therapy of omeprazole, amoxicillin, and clarithromycin for 1 week.
我们的目标是评估基于奥美拉唑的双联和三联疗法根除消化性溃疡疾病中幽门螺杆菌的疗效、安全性及患者依从性。
纳入175例连续的幽门螺杆菌感染并伴有活动性消化性溃疡的患者。通过快速尿素酶试验和组织学分析评估幽门螺杆菌感染情况。患者被随机分为三种治疗组:第1组(56例患者):奥美拉唑,20毫克,每日两次,阿莫西林,1克,每日两次,治疗2周;第2组(61例患者):奥美拉唑,20毫克,每日两次,加阿莫西林,1克,每日两次,甲硝唑,500毫克,每日两次,治疗1周;第3组(58例患者):奥美拉唑,20毫克,每日两次,加阿莫西林,1克,每日两次,克拉霉素,500毫克,每日两次,治疗1周。在治疗停止后4至6周评估溃疡愈合情况和感染治愈情况。按方案分析和意向性分析计算根除率。
治疗后内镜检查时,98.3%的十二指肠溃疡患者愈合。11例患者(6%)失访。第1组患者中55%(95%置信区间[CI]=41%-69%)幽门螺杆菌感染治疗成功;第2组为86%(95%CI=77%-95%)(与第1组相比,p<.001);第3组为93%(95%CI=85%-100%)(与第1组相比,p<.001)。在意向性分析中,第1、2和3组的根除率分别为52%、80%和86%。所有组中超过90%的患者依从性良好。第1组7%的患者、第2组9%的患者和第3组11%的患者报告有副作用。没有患者因副作用而停止治疗。
奥美拉唑-阿莫西林双联疗法治疗2周的根除率显著低于基于奥美拉唑的1周三联疗法。三联疗法耐受性良好,产生的副作用与双联疗法相似。奥美拉唑、阿莫西林和克拉霉素三联疗法治疗1周实现了幽门螺杆菌感染的最高治愈率。